Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trialSandro Pignata, I. L. Ray-Coquard, Frédèric Selle et al.|The Lancet Oncology|2021Cited by 148
Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical SettingsPasquale Lombardi, Gennaro Daniele|Cancers|2023Cited by 52
Exploring Genomic Biomarkers for Pembrolizumab Response: A Real-World Approach and Patient Similarity Network Analysis Reveal DNA Response and Repair Gene Mutations as a SignatureMarco Filetti, Manuela Petti, Mario Occhipinti et al.|Cancers|2024Cited by 3
List of ContributorsEliana Abdelhay, Farhadul Islam, Pavan P. Adiseshaiah et al.|Elsevier eBooks|2018Cited by 0